To summarize, here, we show that CTCs expressing CD47 and/or PD-L1 are more frequently evident in de novo metastatic BC compared to early BC and that they independently predict for poor outcomes in metastatic patients treated with first-line therapy. Here, CD274 is linked to breast cancer.